The Battle over mTOR: An Emerging Theatre in Host–Pathogen Immunity

1. DelgoffeGM, PowellJD (2009) mTOR: taking cues from the immune microenvironment. Immunology 127: 459–465.

2. BhavsarAP, GuttmanJA, FinlayBB (2007) Manipulation of host-cell pathways by bacterial pathogens. Nature 449: 827–834.

3. FrauwirthKA, RileyJL, HarrisMH, ParryRV, RathmellJC, et al. (2002) The CD28 signaling pathway regulates glucose metabolism. Immunity 16: 769–777.

4. Vander HeidenMG, PlasDR, RathmellJC, FoxCJ, HarrisMH, et al. (2001) Growth factors can influence cell growth and survival through effects on glucose metabolism. Mol Cell Biol 21: 5899–5912.

5. WadaHG, IndelicatoSR, MeyerL, KitamuraT, MiyajimaA, et al. (1993) GM-CSF triggers a rapid, glucose dependent extracellular acidification by TF-1 cells: evidence for sodium/proton antiporter and PKC mediated activation of acid production. J Cell Physiol 154: 129–138.

6. FoxCJ, HammermanPS, ThompsonCB (2005) Fuel feeds function: energy metabolism and the T-cell response. Nat Rev Immunol 5: 844–852.

7. WinerS, WinerDA (2012) The adaptive immune system as a fundamental regulator of adipose tissue inflammation and insulin resistance. Immunol Cell Biol

8. KauAL, AhernPP, GriffinNW, GoodmanAL, GordonJI (2011) Human nutrition, the gut microbiome and the immune system. Nature 474: 327–336.

9. JuneCH, BlazarBR, RileyJL (2009) Engineering lymphocyte subsets: tools, trials and tribulations. Nat Rev Immunol 9: 704–716.

10. ZhangY, SatterleeA, HuangL (2012) In Vivo Gene Delivery by Nonviral Vectors: Overcoming Hurdles[quest]. Mol Ther 20: 1298–1304.

11. ZoncuR, EfeyanA, SabatiniDM (2011) mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol 12: 21–35.

12. PowellJD, PollizziKN, HeikampEB, HortonMR (2012) Regulation of Immune Responses by mTOR. Annu Rev Immunol 30: 39–68.

13. van DamTJ, ZwartkruisFJ, BosJL, SnelB (2011) Evolution of the TOR pathway. J Mol Evol 73: 209–220.

14. GougeonML, MelkiMT, SaidiH (2012) HMGB1, an alarmin promoting HIV dissemination and latency in dendritic cells. Cell Death Differ 19: 96–106.

15. BlanchetFP, MorisA, NikolicDS, LehmannM, CardinaudS, et al. (2010) Human immunodeficiency virus-1 inhibition of immunoamphisomes in dendritic cells impairs early innate and adaptive immune responses. Immunity 32: 654–669.

16. ChuluunbaatarU, RollerR, FeldmanME, BrownS, ShokatKM, et al. (2010) Constitutive mTORC1 activation by a herpesvirus Akt surrogate stimulates mRNA translation and viral replication. Genes Dev 24: 2627–2639.

17. NepomucenoRR, BalatoniCE, NatkunamY, SnowAL, KramsSM, et al. (2003) Rapamycin inhibits the interleukin 10 signal transduction pathway and the growth of Epstein Barr virus B-cell lymphomas. Cancer Res 63: 4472–4480.

18. WeichhartT, CostantinoG, PoglitschM, RosnerM, ZeydaM, et al. (2008) The TSC-mTOR signaling pathway regulates the innate inflammatory response. Immunity 29: 565–577.

19. DelgoffeGM, PollizziKN, WaickmanAT, HeikampE, MeyersDJ, et al. (2011) The kinase mTOR regulates the differentiation of helper T cells through the selective activation of signaling by mTORC1 and mTORC2. Nat Immunol 12: 295–303.

20. WangY, WeissLM, OrlofskyA (2010) Coordinate control of host centrosome position, organelle distribution, and migratory response by Toxoplasma gondii via host mTORC2. J Biol Chem 285: 15611–15618.

21. JaramilloM, GomezMA, LarssonO, ShioMT, TopisirovicI, et al. (2011) Leishmania repression of host translation through mTOR cleavage is required for parasite survival and infection. Cell Host Microbe 9: 331–341.

22. MathurRK, AwasthiA, WadhoneP, RamanamurthyB, SahaB (2004) Reciprocal CD40 signals through p38MAPK and ERK-1/2 induce counteracting immune responses. Nat Med 10: 540–544.

23. AlainT, LunX, MartineauY, SeanP, PulendranB, et al. (2010) Vesicular stomatitis virus oncolysis is potentiated by impairing mTORC1-dependent type I IFN production. Proc Natl Acad Sci U S A 107: 1576–1581.

24. PetersonTR, SenguptaSS, HarrisTE, CarmackAE, KangSA, et al. (2011) mTOR complex 1 regulates lipin 1 localization to control the SREBP pathway. Cell 146: 408–420.

25. RubA, DeyR, JadhavM, KamatR, ChakkaramakkilS, et al. (2009) Cholesterol depletion associated with Leishmania major infection alters macrophage CD40 signalosome composition and effector function. Nat Immunol 10: 273–280.

26. ArakiK, TurnerAP, ShafferVO, GangappaS, KellerSA, et al. (2009) mTOR regulates memory CD8 T-cell differentiation. Nature 460: 108–112.

27. LiQ, RaoRR, ArakiK, PollizziK, OdunsiK, et al. (2011) A central role for mTOR kinase in homeostatic proliferation induced CD8+ T cell memory and tumor immunity. Immunity 34: 541–553.

28. WeichhartT, SaemannMD (2009) The multiple facets of mTOR in immunity. Trends Immunol 30: 218–226.

29. AxtellRC, de JongBA, BonifaceK, van der VoortLF, BhatR, et al. (2010) T helper type 1 and 17 cells determine efficacy of interferon-beta in multiple sclerosis and experimental encephalomyelitis. Nat Med 16: 406–412.

30. MeiliR, CronP, HemmingsBA, Ballmer-HoferK (1998) Protein kinase B/Akt is activated by polyomavirus middle-T antigen via a phosphatidylinositol 3-kinase-dependent mechanism. Oncogene 16: 903–907.

31. FothergillT, McMillanNA (2006) Papillomavirus virus-like particles activate the PI3-kinase pathway via alpha-6 beta-4 integrin upon binding. Virology 352: 319–328.

32. AndrabiS, GjoerupOV, KeanJA, RobertsTM, SchaffhausenB (2007) Protein phosphatase 2A regulates life and death decisions via Akt in a context-dependent manner. Proc Natl Acad Sci U S A 104: 19011–19016.

33. PipasJM, LevineAJ (2001) Role of T antigen interactions with p53 in tumorigenesis. Semin Cancer Biol 11: 23–30.

34. PimD, MassimiP, DilworthSM, BanksL (2005) Activation of the protein kinase B pathway by the HPV-16 E7 oncoprotein occurs through a mechanism involving interaction with PP2A. Oncogene 24: 7830–7838.

35. WangG, BarrettJW, StanfordM, WerdenSJ, JohnstonJB, et al. (2006) Infection of human cancer cells with myxoma virus requires Akt activation via interaction with a viral ankyrin-repeat host range factor. Proc Natl Acad Sci U S A 103: 4640–4645.

36. StanfordMM, BarrettJW, NazarianSH, WerdenS, McFaddenG (2007) Oncolytic virotherapy synergism with signaling inhibitors: Rapamycin increases myxoma virus tropism for human tumor cells. J Virol 81: 1251–1260.

37. ClippingerAJ, MaguireTG, AlwineJC (2011) The changing role of mTOR kinase in the maintenance of protein synthesis during human cytomegalovirus infection. J Virol 85: 3930–3939.

38. KudchodkarSB, Del PreteGQ, MaguireTG, AlwineJC (2007) AMPK-mediated inhibition of mTOR kinase is circumvented during immediate-early times of human cytomegalovirus infection. J Virol 81: 3649–3651.

39. LuZ, HuX, LiY, ZhengL, ZhouY, et al. (2004) Human papillomavirus 16 E6 oncoprotein interferences with insulin signaling pathway by binding to tuberin. J Biol Chem 279: 35664–35670.

40. ClippingerAJ, MaguireTG, AlwineJC (2011) Human Cytomegalovirus Infection Maintains mTOR Activity and Its Perinuclear Localization during Amino Acid Deprivation. J Virol 85: 9369–9376.

41. YuY, KudchodkarSB, AlwineJC (2005) Effects of simian virus 40 large and small tumor antigens on mammalian target of rapamycin signaling: small tumor antigen mediates hypophosphorylation of eIF4E-binding protein 1 late in infection. J Virol 79: 6882–6889.

42. O'SheaC, KlupschK, ChoiS, BagusB, SoriaC, et al. (2005) Adenoviral proteins mimic nutrient/growth signals to activate the mTOR pathway for viral replication. EMBO J 24: 1211–1221.

43. WalshD, MohrI (2004) Phosphorylation of eIF4E by Mnk-1 enhances HSV-1 translation and replication in quiescent cells. Genes Dev 18: 660–672.

44. WalshD, AriasC, PerezC, HalladinD, EscandonM, et al. (2008) Eukaryotic translation initiation factor 4F architectural alterations accompany translation initiation factor redistribution in poxvirus-infected cells. Mol Cell Biol 28: 2648–2658.

45. WalshD, PerezC, NotaryJ, MohrI (2005) Regulation of the translation initiation factor eIF4F by multiple mechanisms in human cytomegalovirus-infected cells. J Virol 79: 8057–8064.

46. McMahonR, ZaborowskaI, WalshD (2011) Noncytotoxic inhibition of viral infection through eIF4F-independent suppression of translation by 4EGi-1. J Virol 85: 853–864.